Halister News

(Bloomberg) -- Sanofi still expects 2016 Business EPS to be broadly stable at constant FX, barring unforeseen major adverse events.

• 2Q net sales (aggregate): EU8.87b vs est. EU8.99b
• 2Q Business EPS: EU1.31 vs est. EU1.31
• 2Q Business net income: EU1.68b vs est. EU1.69b
• 2Q Global Business Unit Sales at constant FX:
  • Genzyme: EU1.25b, up 20%
  • Diabetes: EU1.6b, down 3.5%
  • General Medicines: EU4.5b, down 5.6%
  • Vaccines: EU797m, up 6.3%
  • Merial: EU725m, up 9.1%
• 2Q worldwide drug sales:
  • Lantus: EU1.47b vs est. EU1.44b
  • Plavix: EU392m vs est. EU406.9m
  • Lovenox: EU414m vs est. EU411.1m
  • Fabrazyme: EU167m vs est. EU158.8m
  • Cerezyme: EU199m vs est. EU196m
  • Toujeo: EU141m vs est. EU125.3m
  • Aubagio: EU315m vs est. EU307.1m
  • Lemtrada: EU108m vs est. EU103.6m
  • Aprovel: EU175m vs est. EU186.5m
• Conf. call/webcast at 2:30pm CET; dial-in: +33 (0) 1 70 91 87 06
• NOTE: Yday, PREVIEW SANOFI 2Q: Spending on New Drugs, Generics to Weigh